nach oben

Drugs

Erschienen in:

01.02.2001 | Adis New Drug Profile

Omalizumab

verfasst von: Stephanie Easthope, Blair Jarvis

Erschienen in: Drugs | Ausgabe 2/2001

Einloggen, um Zugang zu erhalten

Abstract

▴ Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the Cε3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding.
▴ Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic patients treated with omalizumab.
▴ Omalizumab was also effective in the treatment of children with allergic asthma demonstrating improvements in health-related quality-of-life and significant dosage reductions of inhaled corticosteroids.
▴ Administration of omalizumab to patients with allergic rhinitis resulted in a rapid dose-dependent suppression of serum free IgE levels.
▴ Omalizumab significantly improved health-related quality-of-life and nasal symptoms in patients with seasonal allergicrhinitis.Antihistaminerequirements were also significantly reduced following treatment.
▴ Adverse events were infrequent in clinical trials of omalizumab, and not significantly different from placebo. The most frequent drug-related event was mild to moderate urticaria.

Simons FER. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999 Sep; 104: 534–40PubMedCrossRef

Holgate ST, Corne J, Jardieu P, et al. Treatment of allergic airways disease with anti-IgE. Allergy 1998; 53: 83–8PubMedCrossRef

Frew AJ. Effects of anti-IgE in asthmatic subjects. Thorax 1998 Aug; 53 Suppl. 2: S52–7PubMedCrossRef

Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995 May–Jun; 107: 308–12PubMedCrossRef

Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151(5): 2623–32PubMed

Casale TB, Racine A, Sallas W, et al. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): S357CrossRef

Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997 Jul; 100(1): 110–21PubMedCrossRef

Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000 Aug; 106(2): 253–9PubMedCrossRef

Schoenhoff M, Bates D, Ruppel J, et al. Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti IgE antibody in the cynomolgus monkey [abstract]. J Allergy Clin Immunol 1995 Jan; 95 (1 Pt 2): 356

10.

Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects [see comments]. Am J Respir Crit Care Med 1997 Jun; 155: 1828–34PubMed

11.

Milgrom H, Fick Jr RB, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group [see comments]. N Engl J Med 1999 Dec 23; 341(26): 1966–73PubMedCrossRef

12.

Boulet L-P, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response [see comments]. Am J Respir Crit Care Med 1997 Jun; 155: 1835–40PubMed

13.

Bisberg D, Froehlich J, Schoenhoff M, et al. Multiple administrations of the anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose dependent manner in adolescents and children with moderate to severe allergic asthma [abstract]. J Clin Pharmacol 1996 Sep; 36(9): 859

14.

Saini SS, MacGlashan Jr DW, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FCεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999 May 1; 162: 5624–30PubMed

15.

Busse WW, Fahy JV, Fick RB. A pilot study of the effects of an anti-IGE antibody (E25) on airway inflammation in moderate-severe asthma [abstract]. Am J Respir Crit Care Med 1998 Mar; 157(3) Suppl.: 456

16.

Fick RB, Rohane PW, Gupta N, et al. Anti-inflammatory effects of a recombinant monoclonal anti-IgE (E25) in asthma [abstract]. Am J Respir Crit Care Med 2000 Mar; 161(3) Suppl.: A199

17.

Schoenhoff M, Lin Y, Froehlich J, et al. A pharmacodynamic model describing free IgE concentrations following administration of a recombinant humanized monoclonal anti IgE antibody in humans [abstract]. Pharm Res 1995 Sep; 12(9) Suppl.: 411

18.

Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996 Nov; 279(2): 1000–8PubMed

19.

Milgrom H, Nayak A, Berger W, et al. The efficacy and safety of rhuMAb-E25 in children with allergic asthma [abstract]. J Allergy Clin Immunol 2000 Jun; 105 (1, Pt 2): 1246

20.

Busse W, Corren J, Lanier BQ, et al. rhuMAb-E25, a novel therapy for the treatment of allergic asthma [abstract]. J Allergy Clin Immunol 2000 Jun; 105 (1, Pt 2): 1246CrossRef

21.

Nayak A, LaForce C, Rowe M, et al. rhuMAb-E25 improves quality of life in patients with seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1999 Jan; 103 (1, Pt 2): S49

22.

Casale T, Condemi J, Miller SD, et al. rhuMAb-E25 in the treatment of seasonal allergic rhinitis [abstract]. Ann Allergy Asthma Immunol 1999 Jan; 82(1): 75

23.

Nayak A, Milgrom H, Berger W, et al. rhuMAb-E25 improves quality of life in children with allergic asthma [abstract]. Am J Respir Crit Care Med 2000 Mar; 161(3) Suppl.: 504

24.

National Heart, Lung, and Blood Institute (NHLBI); World Health Organisation (WHO). Global Strategy for Asthma Management and Prevention NHLBI/WHO workshop report. Global initiative for asthma, Jan 1995. Publication no. 95-3659. Available from: URL: http://www.ginasthma.com/xwork.html

25.

Solèr M, Matz J, Townley RG, et al. rhuMAb-E25, a novel therapy for the treatment of allergic asthma (AA) [abstract]. Eur Respir J 2000; 16 Suppl. 31: 10

26.

Buhl R, Solèr M, Fox H, et al. Recombinant humanized monoclonal antibody (rhuMAb) E25 in the prevention of serious asthma exacerbations [abstract]. Eur Respir J 2000; 16 Suppl. 31: 277s.

27.

Kishiyama JL, Lainer BQ, Corren J, et al. rhuMAb-25 (E25) improves asthma-specific quality of life in patients with allergic asthma [abstract]. 17th International Congress of Allergology and Clinical Immunology; 2000 Oct 15–20; Sydney, Suppl. 2: 115

28.

Novartis Inc. Xolair®. Novartis, Jan 2001. (Data on file)

29.

Casale T, Condemi J, Bernstein JA, et al. Safety of readministration of rhuMAb-E25 in seasonal allergic rhinitis [abstract]. Ann Allergy Asthma Immunol 2000 Jan; 84(1): 125

Titel: Omalizumab
verfasst von: Stephanie Easthope
Blair Jarvis
Publikationsdatum: 01.02.2001
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 2/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200161020-00008

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2001

Omalizumab

Comparative Review of Topical Ophthalmic Antibacterial Preparations

Interpretation of Antibacterial Susceptibility Reports

Prophylaxis against Herpesvirus Infections in Transplant Recipients

New Insights into the Second Generation Antihistamines

Safety Profiles for the HMG-CoA Reductase Inhibitors